IBDEI2HQ ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39770,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39770,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,39770,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,39770,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,39771,0)
 ;;=Z85.72^^152^2001^98
 ;;^UTILITY(U,$J,358.3,39771,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39771,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,39771,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,39771,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,39772,0)
 ;;=Z85.79^^152^2001^88
 ;;^UTILITY(U,$J,358.3,39772,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39772,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,39772,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,39772,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,39773,0)
 ;;=Z85.820^^152^2001^77
 ;;^UTILITY(U,$J,358.3,39773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39773,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,39773,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,39773,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,39774,0)
 ;;=Z85.828^^152^2001^92
 ;;^UTILITY(U,$J,358.3,39774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39774,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,39774,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,39774,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,39775,0)
 ;;=Z85.71^^152^2001^72
 ;;^UTILITY(U,$J,358.3,39775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39775,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,39775,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,39775,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,39776,0)
 ;;=Z65.8^^152^2001^144
 ;;^UTILITY(U,$J,358.3,39776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39776,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,39776,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,39776,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,39777,0)
 ;;=Z86.11^^152^2001^109
 ;;^UTILITY(U,$J,358.3,39777,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39777,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,39777,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,39777,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,39778,0)
 ;;=Z86.13^^152^2001^76
 ;;^UTILITY(U,$J,358.3,39778,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39778,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,39778,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,39778,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,39779,0)
 ;;=Z86.73^^152^2001^106
 ;;^UTILITY(U,$J,358.3,39779,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39779,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,39779,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,39779,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,39780,0)
 ;;=Z86.79^^152^2001^69
 ;;^UTILITY(U,$J,358.3,39780,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39780,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,39780,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,39780,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,39781,0)
 ;;=Z91.040^^152^2001^57
 ;;^UTILITY(U,$J,358.3,39781,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39781,1,3,0)
 ;;=3^Latex Allergy Status
 ;;^UTILITY(U,$J,358.3,39781,1,4,0)
 ;;=4^Z91.040
 ;;^UTILITY(U,$J,358.3,39781,2)
 ;;=^5063607
 ;;^UTILITY(U,$J,358.3,39782,0)
 ;;=Z92.3^^152^2001^73
